CN110997698B - 充当pd-1拮抗剂的免疫调节剂 - Google Patents

充当pd-1拮抗剂的免疫调节剂 Download PDF

Info

Publication number
CN110997698B
CN110997698B CN201880052406.0A CN201880052406A CN110997698B CN 110997698 B CN110997698 B CN 110997698B CN 201880052406 A CN201880052406 A CN 201880052406A CN 110997698 B CN110997698 B CN 110997698B
Authority
CN
China
Prior art keywords
alkyl
cancer
group
coupling procedure
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880052406.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN110997698A (zh
Inventor
K·W·吉尔曼
J·古德里奇
孙力强
E·穆尔
D·R·兰勒
P·M·斯科拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN110997698A publication Critical patent/CN110997698A/zh
Application granted granted Critical
Publication of CN110997698B publication Critical patent/CN110997698B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201880052406.0A 2017-06-23 2018-06-21 充当pd-1拮抗剂的免疫调节剂 Active CN110997698B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762523903P 2017-06-23 2017-06-23
US62/523,903 2017-06-23
PCT/US2018/038768 WO2018237153A1 (en) 2017-06-23 2018-06-21 IMMUNOMODULATORS ACTING AS PD-1 ANTAGONISTS

Publications (2)

Publication Number Publication Date
CN110997698A CN110997698A (zh) 2020-04-10
CN110997698B true CN110997698B (zh) 2023-12-26

Family

ID=62909620

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880052406.0A Active CN110997698B (zh) 2017-06-23 2018-06-21 充当pd-1拮抗剂的免疫调节剂

Country Status (6)

Country Link
US (1) US11066445B2 (https=)
EP (1) EP3642220A1 (https=)
JP (1) JP7206222B2 (https=)
KR (1) KR102735038B1 (https=)
CN (1) CN110997698B (https=)
WO (1) WO2018237153A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
HRP20210644T8 (hr) 2016-05-19 2021-06-25 Bristol-Myers Squibb Company Imunomodulatori za pet-snimanje
KR102526034B1 (ko) 2016-11-07 2023-04-25 브리스톨-마이어스 스큅 컴퍼니 면역조정제
WO2018200571A1 (en) 2017-04-25 2018-11-01 Arbutus Biopharma Corporation Substituted 2,3-dihydro-1h-indene analogs and methods using same
CN111051332B (zh) 2017-10-03 2024-09-06 百时美施贵宝公司 免疫调节剂
US12083118B2 (en) 2018-03-29 2024-09-10 Arbutus Biopharma Corporation Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
CA3118031A1 (en) * 2018-12-11 2020-06-18 Heidelberg Pharma Research Gmbh Synthesis of (s)-6-hydroxytryptophan and derivatives thereof
KR20210146348A (ko) 2019-03-28 2021-12-03 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
WO2020198676A1 (en) 2019-03-28 2020-10-01 Bristol-Myers Squibb Company Methods of treating tumor
KR20220010535A (ko) * 2019-05-21 2022-01-25 브리스톨-마이어스 스큅 컴퍼니 면역조정제
WO2020243570A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Cell localization signature and combination therapy
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
KR20220016155A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
WO2021055994A1 (en) 2019-09-22 2021-03-25 Bristol-Myers Squibb Company Quantitative spatial profiling for lag-3 antagonist therapy
US20220411499A1 (en) 2019-11-08 2022-12-29 Bristol-Myers Squibb Company LAG-3 Antagonist Therapy for Melanoma
EP4087857B1 (en) * 2020-01-06 2023-11-01 Bristol-Myers Squibb Company Immunomodulators
KR20220161407A (ko) 2020-03-30 2022-12-06 브리스톨-마이어스 스큅 컴퍼니 면역조정제
WO2021226460A1 (en) * 2020-05-08 2021-11-11 Bristol-Myers Squibb Company Immunomodulators
CN111961117B (zh) * 2020-08-19 2022-03-11 中山大学 一种环肽化合物及其应用
IL300813A (en) 2020-08-28 2023-04-01 Bristol Myers Squibb Co LAG-3 antagonist therapy for hepatocellular carcinoma
AU2021334361A1 (en) 2020-08-31 2023-05-11 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
KR20230093282A (ko) 2020-10-23 2023-06-27 브리스톨-마이어스 스큅 컴퍼니 폐암에 대한 lag-3 길항제 요법
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
KR20230160321A (ko) * 2021-03-24 2023-11-23 브리스톨-마이어스 스큅 컴퍼니 면역조정제
CN117858719A (zh) 2021-03-29 2024-04-09 朱诺治疗学股份有限公司 使用检查点抑制剂疗法和car t细胞疗法的组合进行给药和治疗的方法
WO2022221284A2 (en) * 2021-04-12 2022-10-20 Bristol-Myers Squibb Company Cyclic peptide immunomodulators
KR20240089796A (ko) * 2021-10-20 2024-06-20 브리스톨-마이어스 스큅 컴퍼니 면역조정제
CA3224890A1 (en) 2021-10-29 2023-05-04 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
KR20240135661A (ko) 2022-01-26 2024-09-11 브리스톨-마이어스 스큅 컴퍼니 간세포성 암종에 대한 조합 요법
JP7851417B2 (ja) 2022-04-08 2026-04-24 ブリストル－マイヤーズ スクイブ カンパニー 三次リンパ組織様構造の機械学習識別、分類、及び定量化
EP4638503A1 (en) 2022-12-21 2025-10-29 Bristol-Myers Squibb Company Combination therapy for lung cancer
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
CN121889176A (zh) 2023-09-20 2026-04-17 Trimt有限责任公司 用于体内定向pd-l1表达的功能化肽
WO2025245489A1 (en) 2024-05-24 2025-11-27 Bristol-Myers Squibb Company Treatment of tumors in subjects having fgl-1 positive samples

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014151634A1 (en) * 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions
WO2016077518A1 (en) * 2014-11-14 2016-05-19 Bristol-Myers Squibb Company Macrocyclic peptides useful as immunomodulators
WO2016100608A1 (en) * 2014-12-19 2016-06-23 Bristol-Myers Squibb Company Immunomodulators
WO2016126646A1 (en) * 2015-02-04 2016-08-11 Bristol-Myers Squibb Company Immunomodulators
JP2016531922A (ja) * 2013-09-06 2016-10-13 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ 免疫調節剤としての環式ペプチドミメティック化合物

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
JP3127488B2 (ja) * 1990-06-07 2001-01-22 萬有製薬株式会社 エンドセリン拮抗性ペプチド誘導体
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6277818B1 (en) 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
MXPA02006028A (es) * 1999-12-15 2004-08-23 Cubist Pharm Inc Lipopeptidos novedosos como agentes antibacterianos.
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
EP2662089A3 (en) * 2005-10-08 2014-02-19 Potentia Pharmaceuticals, Inc. Compstatin and analogs thereof for eye disorders
JP5605602B2 (ja) 2007-03-26 2014-10-15 国立大学法人 東京大学 環状ペプチド化合物の合成方法
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
JP5818237B2 (ja) 2010-09-09 2015-11-18 国立大学法人 東京大学 Ｎ−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法
EP2647720B1 (en) 2010-12-03 2019-06-19 The University of Tokyo Peptide library production method, peptide library, and screening method
WO2012168944A1 (en) 2011-06-08 2012-12-13 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
WO2013010573A1 (en) 2011-07-18 2013-01-24 Universitaet Muenster Compounds with matrix-metalloproteinase inhibitory activity
CA2868408A1 (en) 2012-03-29 2013-10-03 Aurigene Discovery Technologies Limited Immunomodulating cyclic compounds from the bc loop of human pd1
JP2013253842A (ja) 2012-06-06 2013-12-19 Univ Of Tokyo ｐＨ依存的に標的分子に結合するペプチドのスクリーニング方法
JP6047231B2 (ja) 2012-06-06 2016-12-21 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ β−ヘアピンペプチド模倣薬
BR112015023120A2 (pt) 2013-03-15 2017-11-21 Genentech Inc método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
WO2016039749A1 (en) 2014-09-11 2016-03-17 Bristol-Myers Squibb Company Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
US9732119B2 (en) * 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
CN107207379B (zh) 2014-11-25 2021-08-10 百时美施贵宝公司 用于生物制品的18f-放射性标记的方法和组合物
CA2969067A1 (en) 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Novel pd-l1 binding polypeptides for imaging
US9861680B2 (en) * 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) * 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) * 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
HRP20210644T8 (hr) 2016-05-19 2021-06-25 Bristol-Myers Squibb Company Imunomodulatori za pet-snimanje
KR102526034B1 (ko) 2016-11-07 2023-04-25 브리스톨-마이어스 스큅 컴퍼니 면역조정제
CN111051332B (zh) 2017-10-03 2024-09-06 百时美施贵宝公司 免疫调节剂

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014151634A1 (en) * 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions
JP2016531922A (ja) * 2013-09-06 2016-10-13 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ 免疫調節剤としての環式ペプチドミメティック化合物
WO2016077518A1 (en) * 2014-11-14 2016-05-19 Bristol-Myers Squibb Company Macrocyclic peptides useful as immunomodulators
WO2016100608A1 (en) * 2014-12-19 2016-06-23 Bristol-Myers Squibb Company Immunomodulators
WO2016126646A1 (en) * 2015-02-04 2016-08-11 Bristol-Myers Squibb Company Immunomodulators

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PD-1/PD-L1信号通路抗肿瘤抑制剂的研究进展;李圣男;周子筠;姜珊;陈烨;;中国药物化学杂志(03);全文· *
景涛,何国祥,吴昊,刘建平,王耿,冉擘力,王海东.血管损伤后酪氨酸激酶活性变化与血管紧张素Ⅱ介导的血管平滑肌细胞迁移.重庆医学.2004,(01),全文. *
血管损伤后酪氨酸激酶活性变化与血管紧张素Ⅱ介导的血管平滑肌细胞迁移;景涛,何国祥,吴昊,刘建平,王耿,冉擘力,王海东;重庆医学(01);全文 *

Also Published As

Publication number Publication date
JP2020525429A (ja) 2020-08-27
EP3642220A1 (en) 2020-04-29
KR20200020858A (ko) 2020-02-26
US11066445B2 (en) 2021-07-20
CN110997698A (zh) 2020-04-10
JP7206222B2 (ja) 2023-01-17
KR102735038B1 (ko) 2024-11-28
US20200172578A1 (en) 2020-06-04
WO2018237153A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
CN110997698B (zh) 充当pd-1拮抗剂的免疫调节剂
CN111051332B (zh) 免疫调节剂
KR102526034B1 (ko) 면역조정제
KR102628640B1 (ko) 면역조정제
KR102548798B1 (ko) Pd-1/pd-l1 및 cd80/pd-l1 단백질/단백질 상호작용의 마크로시클릭 억제제
KR102538436B1 (ko) 면역조정제
KR102602643B1 (ko) 면역조정제
CN107223129B (zh) 免疫调节剂
JP6804442B2 (ja) 免疫修飾因子として有用な大環状ペプチド
CN107207568A (zh) 免疫调节剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant